reports
Zhengwei Group Holdings Company Limited: 1 director
A director at Zhengwei Group Holdings Company Limited sold 13,384,000 shares at 0.218HKD and the significance rating of the trade was 55/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over...
Biokarpet S.A: 3 directors
Three Directors at Biokarpet S.A sold 300,000 shares at 2.740EUR. The significance rating of the trade was 76/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly...
NGS Group AB (publ): Delårsrapport januari-mars 2024
NGS Group AB (publ): Delårsrapport januari-mars 2024 Paradigmskifte inom sjuksköterskebemanning i Sverige. Full kraft i Norgeexpansion. Beslut om nyemissioner. Första kvartalet i sammandrag Nettoomsättningen för första kvartalet uppgick till 100 MSEK (141), en minskning med 29%.Rörelseresultatet (EBITDA) för första kvartalet uppgick till -5,5 MSEK (-1,6), rörelsemarginal -5,5% (-1,1).Rörelseresultatet (EBIT) för första kvartalet uppgick till -6,8 MSEK (-2,7), rörelsemarginal -6,8% (-1,9).Resultatet för första kvartalet uppgick till -6,3 MSEK (-2,8).Resultatet per aktie före och...
Altisource Announces First Quarter 2024 Financial Results
Altisource Announces First Quarter 2024 Financial Results LUXEMBOURG, April 25, 2024 (GLOBE NEWSWIRE) -- Altisource Portfolio Solutions S.A. (“Altisource” or the “Company”) (NASDAQ: ASPS), a leading provider and marketplace for the real estate and mortgage industries, today reported financial results for the first quarter 2024. “I am very pleased with our first quarter performance. We generated $4.6 million of Adjusted EBITDA(1), marking our best quarterly performance since the third quarter of 2020, on $36.9 million of service revenue. We are winning meaningful new business and ramping ...
HOOKIPA Pharma Announces Pivotal Phase 2/3 Trial Design for HB-200 in ...
HOOKIPA Pharma Announces Pivotal Phase 2/3 Trial Design for HB-200 in Combination with Pembrolizumab Phase 2/3 pivotal trial design and protocol for HB-200 in combination with pembrolizumab for the first-line treatment of patients with HPV16+ recurrent or metastatic OPSCC aligned with FDA feedback HB-200 accepted for oral abstract presentation at ASCO 2024 Annual Meeting with data from approximately 40 patients treated with HB-200 in combination with pembrolizumab Two additional abstracts for HB-200 and HB-700 accepted for the ASCO 2024 Annual Meeting Company to host investor call at 8:0...
Nasdaq Announces 9% Increase in Quarterly Dividend to $0.24 Per Share
Nasdaq Announces 9% Increase in Quarterly Dividend to $0.24 Per Share NEW YORK, April 25, 2024 (GLOBE NEWSWIRE) -- The Board of Directors of Nasdaq, Inc. (Nasdaq: NDAQ) has declared a regular quarterly dividend of $0.24 per share on the company's outstanding common stock, a 9% increase from the previous quarter. The dividend is payable on June 28, 2024 to shareholders of record at the close of business on June 14, 2024. Future declarations of quarterly dividends and the establishment of future record and payment dates are subject to approval by the Board of Directors. About Nasdaq N...
- Simon Strong
Excellent momentum in new orders
Corero has secured $8m of orders from both existing and new customers in the first four months of FY24E. The group reported a 17% YoY growth rate in annualised recurring revenue (ARR) last year. This level of momentum in orders not only supports our double-digit % growth forecasts, but also validates the Group’s go-to-market strategy. We are forecasting +13% growth in revenues in FY24E to $25.3m (unchanged), With gross margins high at 90%, the drop through rate of incremental revenues to earnin...
Valley National Bancorp Announces First Quarter 2024 Results
Valley National Bancorp Announces First Quarter 2024 Results NEW YORK, April 25, 2024 (GLOBE NEWSWIRE) -- Valley National Bancorp (NASDAQ:VLY), the holding company for Valley National Bank, today reported net income for the first quarter 2024 of $96.3 million, or $0.18 per diluted common share, as compared to the fourth quarter 2023 net income of $71.6 million, or $0.13 per diluted common share, and net income of $146.6 million, or $0.28 per diluted common share, for the first quarter 2023. Excluding all non-core income and charges, our adjusted net income (a non-GAAP measure) was $99.4 m...
Luk Fook Holdings (International) Ltd: 1 director
A director at Luk Fook Holdings (International) Ltd bought 600,000 shares at 17.957HKD and the significance rating of the trade was 87/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over t...
Regeneron and Mammoth Biosciences Collaborate to Pursue Next-Generatio...
Regeneron and Mammoth Biosciences Collaborate to Pursue Next-Generation CRISPR-Based Gene Editing for Multiple Diseases Mammoth’s proprietary ultracompact CRISPR-based gene editing platform and Regeneron’s proprietary delivery technologies set to advance in vivo programs in multiple tissue and cell types Mammoth to receive $100 million total upfront payment and equity investment from Regeneron at signing TARRYTOWN, N.Y., April 25, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) and Mammoth Biosciences, Inc., today announced a collaboration to research, develop and...
Amwell to Participate in Upcoming Investor Conference
Amwell to Participate in Upcoming Investor Conference Boston, April 25, 2024 (GLOBE NEWSWIRE) -- ® (NYSE: AMWL), a leader in hybrid care enablement, announced that the company will participate in the Needham Technology, Media and Consumer Conference. Robert Shepardson, Amwell chief financial officer, will participate in a fireside chat on Tuesday, May 14, at a time to be determined, along with one-on-one investor meetings throughout the day. An audio webcast of the fireside chat will be available at About Amwell Amwell is a leading hybrid care delivery enablement platform ...
Microbix Collaborator Introduces New Lab Accreditation Program
Microbix Collaborator Introduces New Lab Accreditation Program Microbix Product Supporting Testing for Drug-Resistant Sexually-Transmitted Infection MISSISSAUGA, Ontario, April 25, 2024 (GLOBE NEWSWIRE) -- Microbix Biosystems Inc. (TSX: MBX, OTCQX: MBXBF, Microbix®), a life sciences innovator, manufacturer, and exporter, announces that Labquality Ltd., a collaborator and customer, is presenting results of its use of Microbix Quality Assessment Products (“QAPs™”) for accreditation of clinical labs for conducting molecular (“MDx”) tests for antimicrobial-resistant (“AMR”) strains of M. ge...
Morphic Announces Corporate Highlights and Financial Results for the F...
Morphic Announces Corporate Highlights and Financial Results for the First Quarter 2024 - Enrollment continued on target in EMERALD-2 Phase 2b trial of MORF-057 in ulcerative colitis- -Appointed Dr. Simon Cooper as Chief Medical Officer- -Anticipate dosing first patient in GARNET Phase 2 study of MORF-057 in patients with moderate-to-severe Crohn’s disease in second quarter- -Ended first quarter with $658.8 million in cash, cash equivalents, and marketable securities; cash runway into second half of 2027- WALTHAM, Mass., April 25, 2024 (GLOBE NEWSWIRE) -- (Na...
Kirby Corporation Announces 2024 First Quarter Results
Kirby Corporation Announces 2024 First Quarter Results First quarter 2024 earnings per share of $1.19Inland marine experienced strong market conditions with a sequential increase in spot market prices and high-teens operating margins despite a sequential increase in delay daysCoastal operating margins improved to high single to low double-digit rangeBreaking out power generation at KDS as its significance continues to grow, constituting 41% of KDS revenues Kirby repurchased 498,505 shares at an average price of $83.82 for $41.8 million in the 2024 first quarterAcquired 13 barges, including ...
Optinose Provides Corporate Update on XHANCE Launch and Outlook and An...
Optinose Provides Corporate Update on XHANCE Launch and Outlook and Announces Preliminary First Quarter 2024 XHANCE Net Revenue of $14.9 million Conference Call and Webcast to be held April 25, 2024, at 10:00 a.m. Eastern Time YARDLEY, Pa., April 25, 2024 (GLOBE NEWSWIRE) -- (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced corporate updates detailing its commercial plans and expectations for XHANCE® (fluticasone propionate) following the recent FDA approval of a new indication for the treatment of...
Connectone Bancorp, Inc. Reports First Quarter 2024 Results; Declares ...
Connectone Bancorp, Inc. Reports First Quarter 2024 Results; Declares Preferred and Increased Common Dividends ENGLEWOOD CLIFFS. N.J., April 25, 2024 (GLOBE NEWSWIRE) -- ConnectOne Bancorp, Inc. (Nasdaq: CNOB) (the “Company” or “ConnectOne”), parent company of ConnectOne Bank (the “Bank”), today reported net income available to common stockholders of $15.7 million for the first quarter of 2024 compared with $17.8 million for the fourth quarter of 2023 and $23.4 million for the first quarter of 2023. Diluted earnings per share were $0.41 for the first quarter of 2024 compared with $0.46 fo...
Brunswick Exploration Drills 58.1 Meters at 1.59% Li2O Starting From S...
Brunswick Exploration Drills 58.1 Meters at 1.59% Li2O Starting From Surface at Mirage MONTREAL, April 25, 2024 (GLOBE NEWSWIRE) -- Brunswick Exploration Inc. (TSX-V: BRW, OTCQB: BRWXF; “BRW” or the “Company”) is pleased to report the first assays from the Mirage winter drilling campaign where it drilled an additional thirty-five holes. The Mirage Project is located in the Eeyou Istchee-James Bay region of Quebec approximately 40 kilometres south from the Trans-Taiga Road. The winter drill campaign focused on the Central Zone and has continued to intersect multiple wide, well mineralized ...
TELA Bio to Announce First Quarter 2024 Financial Results
TELA Bio to Announce First Quarter 2024 Financial Results MALVERN, Pa., April 25, 2024 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced that the Company will report first quarter 2024 financial results on Thursday, May 9, 2024. TELA Bio’s management will host a conference call and webcast at 4:30 p.m. ET that day to discuss the financial results and provide a corporate update. First Quarter Earnings Conference Call and Webcast DetailsInvestors...
OTC Markets Group Welcomes Roth CH Acquisition Co. to OTCQX
OTC Markets Group Welcomes Roth CH Acquisition Co. to OTCQX NEW YORK, April 25, 2024 (GLOBE NEWSWIRE) -- (OTCQX: OTCM), operator of regulated markets for trading 12,000 U.S. and international securities, today announced (OTCQX: USCTF), a special purpose acquisition company, has qualified to trade on the OTCQX® Best Market. Roth CH Acquisition Co. previously traded on NASDAQ. Roth CH Acquisition Co. begins trading today on OTCQX under the symbol “USCTF.” U.S. investors can find current financial disclosure and Real-Time Level 2 quotes for the company on . Trading on the OTCQX Market of...
Cibus to Report First Quarter 2024 Financial Results on May 9, 2024 an...
Cibus to Report First Quarter 2024 Financial Results on May 9, 2024 and Host Conference Call SAN DIEGO, April 25, 2024 (GLOBE NEWSWIRE) -- Cibus, Inc. (Nasdaq: CBUS), a leading agricultural biotechnology company that uses proprietary gene editing technologies to develop plant traits (or specific genetic characteristics) in seeds, today announced that the company will report first quarter 2024 financial results on Thursday, May 9, 2024. Cibus’ management team will host a conference call and audio webcast at 4:30 p.m. ET on that day to discuss the financial results and other company updates...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.